Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Issue 8 (16th February 2017)

• Record Type: Journal Article
• Authors: Handels, Ron L.H.; Vos, Stephanie J.B.; Kramberger, Milica G.; Jelic, Vesna; Blennow, Kaj; van Buchem, Mark; van der Flier, Wiesje; Freund‐Levi, Yvonne; Hampel, Harald; Olde Rikkert, Marcel; Oleksik, Ania; Pirtosek, Zvezdan; Scheltens, Philip; Soininen, Hilkka; Teunissen, Charlotte; Tsolaki, Magda; Wallin, Asa K.; Winblad, Bengt; Verhey, Frans R.J.; Visser, Pieter Jelle
• Is Part Of: Alzheimer's & dementia. Volume 13:Issue 8(2017)
• Page Start: 903
• Page End: 912
• Publication Date: 2017-02-16
• Subjects: Dementia -- Alzheimer's disease -- Mild cognitive impairment -- Prognosis -- Risk -- Progression -- Predict -- Conversion -- Reclassification -- Risk prediction model; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2016.12.015
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0–1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow‐up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.